BioSpace News Archive

Together with the first and second tranches, closing March 25, and April 5, respectively, the Company has now raised a total of $1,500,000.

MitoChem Therapeutics, Inc. , a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to its lead compound, MC16, for treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is an inherited degenerative disease of the retina caused by genetic mutations that lead to severe vision loss and blindness

Researchers have found a long-sought enzyme that prevents cancer by enabling the breakdown of proteins that drive cell growth, and that causes cancer when disabled.

Medecision, an integrated health management company supporting virtual care and digital health, announced Ken Young will be named president and CEO effective immediately. Young succeeds current president and CEO Deborah Gage . She and Chief Administrative Officer Jennifer Ponski will leave Medecision effective today.

CytomX Therapeutics, Inc. announced that on April 1, 2021, the Company granted a new employee an option to purchase a total of 120,000 shares of the Company’s common stock at an exercise price per share equal to $7.87, which was the closing trading price on April 1, 2021, the date of the grant.

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced it has commenced an underwritten registered public offering of $25 million aggregate principal amount of senior notes due 2026, subject to market and certain other conditions.

AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment. On April 14, 2021, the Company issued the aggregate of 515,156 common shares at $8.25 per share

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, participated in a Prader-Willi Syndrome (PWS) DCCR Town Hall on Wednesday, April 14, 2021.